Oxidative stress in patients after kidney transplantation

Czech version

Authors: J. Vostálová ¹; A. Galandáková ¹; P. Štrebl ²; J. Zadražil ²
Authors‘ workplace: Ústav lékařské chemie a biochemie Lékařské fakulty UP Olomouc, přednostka prof. RNDr. Jitka Ulrichová, CSc. ¹; III. interní nefrologická, revmatologická a endokrinologická klinika Lékařské fakulty UP a FN Olomouc, přednosta prof. MU Dr. Josef Zadražil, CSc. ²
Published in: Vnitř Lék 2013; 59(4): 296-300
Category: Review

Overview

Successfull kidney transplantation (KT) leads not only to normalization of renal excretory function, but also to modification of the metabolic and endocrine kidney function. The most common cause of morbidity and mortality in patients after KT are cardiovascular diseases which development is also associated with oxidative stress (OS). KT and the post‑transplantation period are associated with increased OS that could gradually decrease. Some immunosuppressive drugs also contribute to increase of OS, especially compounds from a group of calcineurin inhibitors and thus indirectly contribute to increased risk of cardiovascular complications.

Key words:
oxidative stress – renal transplantation – ischemia/ reperfusion injury – immunosuppressive agents

Sources

1. Viklický O et al. Transplantace ledviny v klinické praxi. Praha: Grada Publishing 2008.

2. Viklický O. Kardiovaskulární onemocnění a jejich rizikové faktory po transplantaci ledviny. Postgraduální medicína 2008; 9: 1008– 1011.

3. Liefeldt L, Budde K. Risk factors for cardiovascular disease in renal transplant recipients and strategies to minimize risk. Transplant International. European Society for Organ Transplantation 2010; 23: 1191– 1204.

4. Roberts MA, Hare DL, Ratnaike S et al. Cardiovascular biomarkers in CKD: pathophysiology and implications for clinical management of cardiac disease. Am J Kidney Dis 2006; 48: 341– 360.

5. Pita- Fernandez S, Pertega- Diaz S, Valdes- Canedo F et al. Incidence of cardiovascular events after kidney transplantation and cardiovascular risk scores: study protocol. BMC Cardiovasc Disord. 2011; 11: 2.

6. Vostálová J, Galandáková A, Štrebl P et al. Oxidační stres u pacientů s onemocnění ledvin. Vnitř Lék 2012; 58: 202– 207.

7. Eltzschig HK, Eckle T. Ischemia and reperfusion– from mechanism to translation. Nat Med 2011; 17: 1391– 1401.

8. Makropoulos W, Kocher K, Heintz B et al. Urinary thymidine glycol as a biomarker for oxidative stress after kidney transplantation. Ren Fail 2000; 22: 499– 510.

9. Biernacki M, Bigda J, Jankowski K et al. Increased serum levels of markers of oxidative stress during kidney transplantation. Transplant Proc 2002; 34: 544– 545.

10. Araujo M, Welch WJ. Oxidative stress and nitric oxide in kidney function. Curr Opin Nephrol Hypertens 2006; 15: 72– 77.

11. Snoeijs MG, van Heurn LW, Buurman WA. Biological modulation of renal ischemia- reperfusion injury. Curr Opin Organ Transplant 2010; 15: 190– 199.

12. Dołęgowska B, Błogowski W, Domański L. Clinical evidence of the association between serum perioperative changes in xanthine metabolizing enzymes activity and early post‑transplant kidney allograft function. J Am Coll Surg 2010; 211: 587– 595.

13. Yamakura F, Kawasaki H. Post‑translational modifications of superoxide dismutase. Biochim Biophys Acta 2010; 1804: 318– 325.

14. Perico N, Cattaneo D, Sayegh MH et al. Delayed graft function in kidney transplantation. Lancet 2004; 364: 1814– 1827.

15. Chatterjee PK. Novel pharmacological approaches to the treatment of renal ischemia– reperfusion injury: a comprehensive review. Naunyn Schmiedebergs Arch Pharmacol 2007; 376: 1– 43.

16. Chatauret N, Thuillier R, Hauet T. Preservation strategies to reduce ischemic injury in kidney transplantation: pharmacological and genetic approaches. Curr Opin Organ Transplant 2011; 16: 180– 187.

17. Nankivell BJ, Kuypers DR. Diagnosis and prevention of chronic kidney allograft loss. Lancet 2011; 378: 1428– 1437.

18. Simmons EM, Langone A, Sezer MT et al. Effect of renal transplantation on biomarkers of inflammation and oxidative stress in end‑stage renal disease patients. Transplantation 2005; 79: 914– 919.

19. Zahmatkesh M, Kadkhodaee M, Mahdavi– Mazdeh M et al. Oxidative stress status in renal transplant recipients. Exp Clin Transplant 2010; 8: 38– 44.

20. Joo DJ, Huh KH, Cho Y et al. Change in serum lipid peroxide as an oxidative stress marker and its effects on kidney function after successful kidney transplantation. Transplant Proc 2010; 42: 729– 732.

21. Vural A, Yilmaz MI, Caglar K et al. Assessment of oxidative stress in the early posttransplant period: comparison of cyclosporine A and tacrolimus‑based regimens. Am J Nephrol 2005; 25: 250– 255.

22. Moreno JM, Ruiz MC, Ruiz N et al. Modulation factors of oxidative status in stable renal transplantation. Transplant Proc 2005; 37: 1428– 1430.

23. Zadražil J, Horák P, Štrebl P et al. In vivo oxidized low- density lipoprotein (ox- LDL) aopp and tas after kidney transplantation: a prospective, randomized one year study comparing cyclosporine A and tacrolimus based regiments. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2012; 156: 14– 20.

24. Vostálová J, Galandáková A, Svobodová AR et al. Time– course evaluation of oxidative stress‑related biomarkers after renal transplantation. Ren Fail 2012; 34: 413– 419.

25. Vostálová J, Galandáková A, Svobodová AR et al. Stabilization of oxidative stress 1 year after kidney transplantation: effect of calcineurin immunosuppressives. Ren Fail 2012; 34: 952– 959.

26. Emre H, Keles M, Yildirim S et al. Comparison of the oxidant– antioxidant parameters and sialic acid levels in renal transplant patients and peritoneal dialysis patients. Transplant Proc 2011; 43: 809– 812.

27. Cueto– Manzano AM, Morales– Buenrostro LE, González– Espinoza L et al. Markers of inflammation before and after renal transplantation. Transplantation 2005; 80: 47– 51.

28. Cristol JP, Vela C, Maggi MF et al. Oxidative stress and lipid abnormalities in renal transplant recipients with or without chronic rejection. Transplantation 1998; 65: 1322– 1328.

29. Lojek A, Černý J, Nĕmec P et al. Phagocyte‑induced oxidative stress in patients with haemodialysis treatment and organ transplantation. Biofactors 1998; 8: 165– 168.

30. Ramezani M, Nazemian F, Shamsara J et al. Effect of Omega- 3 Fatty Acids on Plasma Level of 8- Isoprostane in Kidney Transplant Patients. J Ren Nutr 2010; 17: 196– 199.

31. Haririan A, Metireddy M, Cangro C et al. Association of Serum Uric Acid With Graft Survival After Kidney Transplantation: A Time– Varying Analysis. Am J Transplant 2011; 11: 1943– 1150.

32. Zachara BA, Gromadzińska J, Wasowicz W et al. Red blood cell and plasma glutathione peroxidase activities and selenium concentration in patients with chronic kidney disease: a review. Acta Biochim Pol 2006; 53: 663– 677.

33. Cantarovich D, Vistoli F, Soulillou JP. Immunosuppression minimization in kidney transplantation. Front Biosci 2008; 13: 1413– 1432.

34. Viklický O. Imunosupresivní terapie. Postgraduální medicina 2008; 9: 996– 1006.

35. Walker RJ, Lazzaro VA, Duggin GG et al. Evidence that alterations in renal metabolism and lipid peroxidation may contribute to cyclosporine nephrotoxicity. Transplantation 1990; 50: 487– 492.

36. Ahmed SS, Strobel HW, Napoli KL et al. Adrenochrome reaction implicates oxygen radicals in metabolism of cyclosporine A and FK- 506 in rat and human liver microsomes. J Pharmacol Exp Ther 1993; 265: 1047– 1054.

37. Krauskopf A, Buetler TM, Nguyen NS et al. Cyclosporin A‑induced free radical generation is not mediated by cytochrome P– 450. Br J Pharmacol 2002; 135: 977– 986.

38. Calo LA, Davis PA, Giacon B et al. Oxidative stress in kidney transplant patients with calcineurin inhibitor‑induced hypertesion: Effect of ramipril. J Cardiovasc Pharmacol 2002; 40: 625– 631.

39. Varghese Z, Fernando RL, Turakhia G et al. Oxidizability of Low-Density Lipoproteins From Neoral and Tacrolimus- Treated Renal Transplant Patients. Transplant Proc 1998; 30: 2043– 2046.

40. Varghese Z, Fernando RL, Turakhia G et al. Calcineurin inhibitors enhance low- density lipoprotein oxidation in transplant patients. Kidney Int Suppl 1999; 71: S137– S140.

41. Cofan F, Cofan M, Campos B et al. Effect of calcineurin inhibitors on low- density lipoprotein oxidation. Transplant Proc 2005; 37: 3791– 3793.

42. Martínez Castelao A, Ramos R, Serón D et al. Effect of cyclosporin and tacrolimus on lipoprotein oxidation after renal transplantation. Nekrologia 2002; 22: 364– 369.

43. Perrea DN, Moulakakis KG, Poulakou MV et al. Correlation between oxidative stress and immunosuppressive therapy in renal transplant recipients with an uneventful postoperative course and stable renal function. Int Urol Nephrol 2006; 38: 343– 348.

44. Morena M, Vela C, Garrigue V et al. Low-Density Lipoprotein Composition and Oxidation Are Not Influenced by Calcineurin Inhibitors in Renal Transplant Patients. Transplant Proc 2000; 32: 2785– 2786.

45. Štrebl P, Horčička jr. V, Krejči K et al. Oxidative stress after kidney transplantation: The role of immunosuppression. Dial Transplant 2010; 39: 391– 394.

46. Zadražil J, Štrebl P, Krejčí K et al. Effect of different calcineurin inhibitors on AOPP and TAS after kidney transplantation. Clin Biochem 2010; 43: 559– 565.

47. Calò LA, Dall‘Amico R, Pagnin E et al. Oxidative stress and post‑transplant hypertension in pediatric kidney- transplanted patients. J Pediatr 2006; 149: 53– 57.